Mesothelin-Binding Peptide Inhibits Cell Migration and Enables Targeted Delivery of a Mitochondrial-Membrane-Damaging Peptide to Pancreatic Tumors
Biomaterials Research · 01.01.2026 · 30
DOI: 10.34133/bmr.0361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials Research, online erschienen am 11.05.2026. Verfasst von Min-Sung Park und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Mesothelin (MSLN) is up-regulated in many tumors, including pancreatic tumors, making it a promising therapeutic target. We used a phage-displayed peptide library to identify an MSLN-binding peptide. CTILWSLTC, synthesized in cyclic form (MSLNpep), was selected from the library. MSLNpep bound preferentially to MSLN-high versus MSLN-low cells, internalized efficiently, and bound recombinant MSLN more strongly than a control peptide. MSLNpep treatment reduced migration and invasion in MSLN-high tumor cells. To enable targeted cytotoxicity, we generated chimeras linking MSLNpep to L-form or D-form mitochondrial-membrane-damaging peptides (MSLNpep-KLA and MSLNpep-kla, respectively). MSLNpep-kla—and, to a lesser extent, MSLNpep-KLA—exhibited selective cytotoxicity toward MSLN-high versus MSLN-low cells. Systemic MSLNpep-kla, but not MSLNpep-KLA, suppressed orthotopic pancreatic tumor growth, increased survival, and produced no detectable hepatic or renal toxicity in mice. MSLNpep-kla also induced cytotoxicity in patient-derived pancreatic cancer organoids proportionate to MSLN expression. Analysis of a public single-cell RNA-sequencing dataset of human pancreatic cancer tissues revealed that MSLN was predominantly expressed in malignant ductal cells while showing negligible expression in normal ductal cells and stromal cells. These findings demonstrate that MSLNpep inhibits tumor-cell migration and enables targeted delivery of therapeutic payloads to MSLN-high pancreatic tumors, supporting its use as a peptide ligand for cancer therapy.
Autor:innen und Institutionen
- Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
- BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
- CMRI, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
- Department of Molecular Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
- Laboratory Animal Center, K-Medi Hub, Daegu 41061, Republic of Korea.
- College of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
ORCID-Profile: Byungheon Lee
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Park, M. S., Gunassekaran, G. R., Lee, S. M., Vadevoo, S. M. P., Jo, D. G., Kim, S., Ha, E., Kim, S. K., Ahn, H., Chung, S. J., Kang, G., Lee, M. R., Woo, S. M., Kim, Y. H., & Lee, B. (2026). Mesothelin-Binding Peptide Inhibits Cell Migration and Enables Targeted Delivery of a Mitochondrial-Membrane-Damaging Peptide to Pancreatic Tumors. Biomaterials Research, 30. https://doi.org/10.34133/bmr.0361
Vancouver
Park MS, Gunassekaran GR, Lee SM, Vadevoo SMP, Jo DG, Kim S, et al. Mesothelin-Binding Peptide Inhibits Cell Migration and Enables Targeted Delivery of a Mitochondrial-Membrane-Damaging Peptide to Pancreatic Tumors. Biomaterials Research. 2026;30. doi:10.34133/bmr.0361
BibTeX
@article{Park2026,
author = {Park, Min-Sung and Gunassekaran, Gowri Rangaswamy and Lee, Seok-Min and Vadevoo, Sri Murugan Poongkavithai and Jo, Dong-Gyun and Kim, Soyoun and Ha, Eunji and Kim, Sang-Kyun and Ahn, Hyejin and Chung, Sang-Jeon and Kang, Gyeongmin and Lee, Mi Rim and Woo, Sang Myung and Kim, Yun-Hee and Lee, Byungheon},
title = {Mesothelin-Binding Peptide Inhibits Cell Migration and Enables Targeted Delivery of a Mitochondrial-Membrane-Damaging Peptide to Pancreatic Tumors},
journal = {Biomaterials Research},
year = {2026},
volume = {30},
doi = {10.34133/bmr.0361}
}
EUVIMED